Evidence map›Paper›PMID 39372507›Full record

ArticleApplied biosafety : journal of the American Biological Safety Association2024

Practical Questions for Securing Nucleic Acid Synthesis.

Sophie Rose, Tessa Alexanian, Max Langenkamp, Helena Cozzarini, James Diggans

Abstract read
In one paragraph

Article in Applied biosafety : journal of the American Biological Safety Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Implementing emerging customer screening standards for nucleic acid synthesis.Frontiers in bioengineering and biotechnology · 2026
    Article
  4. ADAPT: a programme for the advanced detection of AI-enabled pathogenic threats.Frontiers in bioengineering and biotechnology · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Why implementation gaps could undermine synthetic nucleic acid oversight.Frontiers in bioengineering and biotechnology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sophie RoseThe Centre for Long-Term Resilience, London, United Kingdom.
Tessa AlexanianInternational Biosecurity and Biosafety Initiative for Science (IBBIS), Geneva, Switzerland.ORCID https://orcid.org/0000-0003-1108-7124
Max LangenkampSecureDNA, Zug, Switzerland.
Helena CozzariniIndependent, Vienna, Austria.
James DiggansTwist Bioscience, South San Francisco, California, USA.ORCID https://orcid.org/0000-0003-3871-2380

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Affordable and accurate nucleic acid synthesis is foundational to modern biotechnology, but raises security concerns because it facilitates the construction of pathogens and other potentially dangerous biological agents. Nucleic acid synthesis screening can reduce the risk of providing potentially harmful nucleic acids to those without a legitimate use for them. Governments, industry associations, and biosecurity organizations have offered guidance on synthesis screening for a decade, and are now considering how to translate industry best practices into regulatory frameworks. Methods: A review of existing guidance documents, policy proposals, and other published literature was performed. Results: We distinguish five categories of practical questions for policymakers: challenges associated with customer screening, sequence screening, the interaction between domestic and global regulations, commercial implications of screening, and finally, challenges associated with benchtop nucleic acid synthesis devices. There are a number of recommendations in public literature that target the implementation of robust customer and sequence screening, several of which have been incorporated into the recent United States White House Executive Order on artificial intelligence. There appears to be fewer solutions proposed to address challenges associated with the global screening landscape, or the commercial implications of screening requirements, and limited discussion on securing the benchtop synthesis landscape. Discussion and Conclusion: This paper aims at providing a comprehensive resource for policymakers, outlining a set of questions governments, and other stakeholders, must answer when implementing screening requirements to secure nucleic acid synthesis.

Indexed as

biosecurityDNA synthesisnucleic acid synthesis screeningsynthetic biologysynthetic genomics

Identifiers

PMID39372507
PMCPMC11447131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.